BIOASTER, a French Technology Research Institute focused on infectious diseases and microbiology, has appointed Tom Shepherd as Chief Executive. He succeeds Jacques Berger who, following his retirement from his previous position as Directeur Général Délégué of Sanofi Pasteur, had been asked to set up BIOASTER’s corporate and laboratory operations and establish the foundations for its future growth into a leading research institute.
Shepherd has committed more than 30 years to life science research, development and commercialisation, primarily in the pharmaceutical and biotechnology industries.
He has held CEO positions with CXR Biosciences and Vascular Flow Technologies in Scotland and with Neurotech in Paris and Rhode Island, US, as well as Head of Business Development responsibilities at Kymab in Cambridge, UK, Intrabiotics Pharmaceuticals and ICN (Valeant) Pharmaceuticals in California, US and various executive positions in marketing and R&D in the UK, Australia and South Korea.
BIOASTER is a Technology Research Institute with the strategic objective of developing research programmes and advanced technology centres in collaboration with public and private partners, to help overcome health and product development challenges relating to therapeutics, vaccines, diagnostics and nutrition in the fields of infectious diseases and microbiology.
